Uncovering the Financial and Strategic Position of WST Amidst Market Dynamics
An announcement from West Pharmaceutical Services ( (WST) ) is now available. West Pharmaceutical Services reported a slight decline in third-quarter 2024 net sales to $746.9 million and a drop in adjusted earnings per share to $1.85 from $2.16 last year. Despite these declines, the company raised its full-year sales and EPS guidance due to favorable currency movements. West’s proprietary products segment saw a minor sales decline, while contract-manufactured products experienced slight growth.